Skip to main content

Table 1 Characteristics of patients aged less than 40 years with immunohistochemistry results

From: Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials

Characteristic All patients
(N= 549)
Node negative patients (N= 341)
  No. of Patients % No. of Patients %
Age, years     
Median (range) 36.8 (23 to 40) 36.8 (25 to 40)
Age distribution     
   ≥ 30 years 57 10 40 12
   31 to 35 years 178 32 107 31
   35 to 40 years 314 58 194 57
Pathological tumor size     
   T1a and T1b 37 7 30 10
   T1c 296 60 241 64
   T2 158 32 82 26
   T3 6 1 2 1
   Missing 32   26  
Pathological nodal status     
   Negative 341 63 341 100
   Positive 204 37 0 0
   Missing 4    
Surgery     
   Breast conserving 446 81 299 88
   Mastectomy 102 19 42 12
   Missing 1   0  
Adjuvant chemotherapy1     
   No 326 60 304 89
   Yes 221 40 37 11
   Missing 2   0  
ER status     
   Positive 310 66 115 41
   Negative 158 34 165 59
   Missing 81   61  
PgR status     
   Positive 223 48 141 51
   Negative 241 52 136 49
   Missing 85   64  
Tumor type     
   Ductal 497 96 306 96
   Lobular 17 3 10 3
   Other 5 1 4 1
   Missing 30   21  
Histological grade     
   I 76 15 54 17
   II 165 32 93 29
   III 276 53 172 54
   Missing 32   22  
Lymphangio invasion     
   None 357 69 243 76
   1-5 vessels 86 17 49 15
   > 5 vessels 76 14 27 9
   Missing 30   22  
HER2 status     
   Negative 346 74 216 63
   Positive 119 26 64 19
   Missing 84   61  
P53 status     
   Negative 331 71 198 72
   Positive 133 29 78 28
   Missing 85   65  
Molecular subtype     
   Luminal A 154 34 79 29
   Luminal B 157 34 86 32
   HER-2 35 8 90 34
   Basal (triple-negative) 111 24 14 5
   Missing 92   72  
  1. 1 EORTC trial 10854 randomized between one course of peri-operative chemotherapy which was not considered as prolonged chemotherapy.
  2. Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.